At a glance
ClinicalIndex Comparison RecordN/ACompleted· 278 enrolled
Drug / intervention
Bolus Insulin Patch (Calibra Finesse) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents
In Brief
A clinical study evaluating Bolus Insulin Patch (Calibra Finesse) and Insulin Pen (Novo-Nordisk FlexPen®) for Diabetes Mellitus, Type 2. Completed, enrolled 278 participants across 52 sites in 4 countries.
Detailed Summary
To compare glycemic control and treatment satisfaction using a novel bolus insulin patch (Finesse) versus a pen for initiating and managing bolus insulin dosing in patients with T2DM not achieving glycemic targets on basal insulin with/without anti-hyperglycemic agents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesFrance, Germany, United Kingdom, United States
CollaboratorsMedpace, Inc.
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedSep 2015
Primary CompletionAug 2017
TodayJul 2026
First PostedSep 7, 2015
Enrollment StartAug 1, 2015
Primary CompletionAug 31, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 10.8 years ago
Interventions
Bolus Insulin Patch (Calibra Finesse)device
Insulin Pen (Novo-Nordisk FlexPen®)device